Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study

April 7, 2026 updated by: Fred Hutchinson Cancer Center

IMPACT: Improving Access to Cancer Survivorship Via Telehealth

This trial studies how well self-generated survivorship care plans and telehealth education works in improving knowledge and self-efficacy in cancer survivors living in rural areas. Patients living in rural areas often face barriers to survivorship care and report unmet needs. A survivorship care plan created by the patient (self-generated) may help them to better transition from oncology to primary care and improve communication between care teams in order to meet these needs and create better health outcomes. Telehealth is a way of delivering health care services from a distance, including patient education. Combining a self-generated survivorship care plan with telehealth education may help to improve knowledge and self-efficacy in cancer survivors.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OUTLINE:

Patients complete a questionnaire at baseline (paper, online, or telephone-based) and have medical records reviewed and are assigned to 1 of 3 cohorts.

COHORTS A AND B: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive a self-generated SCP (i.e., generated from baseline questionnaire responses).

ARM II: Patients receive a self-generated SCP as in Arm I. Patients also receive a 30-minute telephone-based educational counseling session on survivorship care administered by trained lay health counselors.

COHORT C: Patients are randomized to 1 of 3 arms.

ARM III: Patients receive generic information on survivorship care on study.

ARM IV: Patients receive generic information on survivorship care and a self-generated SCP as in Arm I on study.

ARM V: Patients receive generic information on survivorship care as well as a self-generated SCP as in Arm I and a telephone-based educational counseling session as in Arm II on study.

PRIMARY CARE PROVIDERS: Primary care providers complete a questionnaire about perceptions of the SCP and self-efficacy in providing survivorship care.

ONCOLOGY CLINICS: Participants complete Organizational Readiness to Change Assessment (ORCA) questionnaire and participate in a qualitative interview about perceptions of implementation of survivorship care.

After completion of study, patients are followed up at approximately 8 weeks.

Study Type

Interventional

Enrollment (Actual)

261

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Washington
      • Seattle, Washington, United States, 98109
        • Fred Hutch/University of Washington Cancer Consortium

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Cancer survivors who have completed curative therapy within the past 5 years (may still currently be on long-term/targeted non-cytotoxic agent maintenance therapy, e.g., tamoxifen or aromatase inhibitors for breast cancer survivors; androgen deprivation therapy for prostate cancer survivors)
  • History of either adult-onset (age >= 18) lymphoma, breast, colorectal, lung, or prostate cancer
  • Able to perform all study requirements, including responding to questionnaires
  • Willing to be randomized
  • Capable of providing informed consent
  • Consent to release oncology and primary care medical records
  • English or Spanish speakers
  • PRIMARY CARE PROVIDERS: PCPs responsible for delivering primary care to IMPACT study participants will be contacted about participating in the study after participant enrollment into the study.
  • ONCOLOGY STAFF: Oncology Staff (Oncologists, Nurse Practitioners, Physician's assistants) will be recruited from sites involved in the IMPACT study
  • CLINIC ADMINISTRATORS: Clinic administrators will be recruited from sites involved in the IMPACT study

Exclusion Criteria:

  • Currently on palliative or hospice care, or considering transferring to such care within the next 3 months
  • Lacks telephone access
  • Lacks mailing address or ability to receive study materials electronically
  • Currently being followed in a pediatric clinical setting (either for primary care or for cancer care)
  • History of having had > 1 cancer type diagnosed and treated (exception is for skin cancers treated with surgical excision alone; also, individuals who only have had relapse of their initial cancer remain eligible so long as they have completed curative therapy and meet all other eligibility criteria)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm I (patient-generated SCP)
Patients receive a self-generated SCP (i.e., generated from baseline questionnaire responses).
Other: Questionnaire Administration
Ancillary studies
Other: Survivorship Care Plan
Receive patient-generated SCP
Experimental: Arm II (patient-generated SCP, counseling)
Patients receive a self-generated SCP as in Arm I. Patients also receive a 30-minute telephone-based educational counseling session on survivorship care administered by trained lay health counselors.
Other: Questionnaire Administration
Ancillary studies
Other: Survivorship Care Plan
Receive patient-generated SCP
Other: Educational Intervention
Receive telephone-based educational counseling session
Other Names:
  • Education for Intervention
  • Intervention by Education
  • Intervention through Education
  • Intervention, Educational
Active Comparator: Arm III (generic information)
Patients receive generic information on survivorship care on study.
Other: Questionnaire Administration
Ancillary studies
Other: Supportive Care
Receive generic information on survivorship care
Other Names:
  • Supportive Therapy
  • Symptom Management
Active Comparator: Arm IV (generic information, patient-generated SCP)
Patients receive generic information on survivorship care and a self-generated SCP as in Arm I on study.
Other: Questionnaire Administration
Ancillary studies
Other: Survivorship Care Plan
Receive patient-generated SCP
Other: Supportive Care
Receive generic information on survivorship care
Other Names:
  • Supportive Therapy
  • Symptom Management
Experimental: Arm V (generic information, patient-generated SCP, counseling)
Patients receive generic information on survivorship care as well as a self-generated SCP as in Arm I and a telephone-based educational counseling session as in Arm II on study.
Other: Questionnaire Administration
Ancillary studies
Other: Survivorship Care Plan
Receive patient-generated SCP
Other: Educational Intervention
Receive telephone-based educational counseling session
Other Names:
  • Education for Intervention
  • Intervention by Education
  • Intervention through Education
  • Intervention, Educational
Other: Supportive Care
Receive generic information on survivorship care
Other Names:
  • Supportive Therapy
  • Symptom Management

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accuracy of survivors' self-generated survivorship care plans (SCPs) in relation to those based on medical record abstraction
Time Frame: Up to 8 weeks
Will measure the accuracy of participants' SCPs by comparing their self-reported medical history collected via questionnaire, with data abstracted from medical records. Accuracy will be reported by percentage of missing data in the self-generated SCP compared to medical records, and percentage of incorrect data in the self-generated SCP compared to medical records.
Up to 8 weeks
Proportion of survivors who receive the phone-based education session within the study time period
Time Frame: Up to 8 weeks
Up to 8 weeks
Proportion of survivors who complete the follow-up questionnaire within the study time period
Time Frame: Up to 8 weeks
Up to 8 weeks
Response rate among primary care providers (PCPs) to the PCP survey
Time Frame: Up to 8 weeks
Up to 8 weeks
Initial participation rate of cancer survivors identified from community-based or partner practices, and Cancer Surveillance System of Western Washington
Time Frame: Up to 8 weeks
Up to 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participant perceived self-efficacy: questionnaire using the PROMIS Global 10 and health related self-efficacy scales
Time Frame: Up to 8 weeks
The effects of the intervention versus (vs.) control on participant perceived self-efficacy will be measured at baseline and at the end of the study via a questionnaire using the PROMIS Global 10 and health related self-efficacy scales.
Up to 8 weeks
Survivorship knowledge
Time Frame: Up to 8 weeks
The effects of the intervention vs. control on survivorship knowledge will be measured at baseline and at the end of the study via a questionnaire.
Up to 8 weeks
PCP self-efficacy towards survivorship care
Time Frame: Up to 8 weeks
The effects of the intervention vs. control on PCP self-efficacy towards survivorship care will be measured at baseline and at the end of the study via a questionnaire using the PROMIS Global 10 and health related self-efficacy scales.
Up to 8 weeks
Local oncology clinics' attitudes towards survivorship care implementation
Time Frame: Up to 8 weeks
Assess oncology practitioners' and clinic administrators' views on utility and feasibility of implementing SCPs in target clinics, using the ORCA (Organizational Readiness to Change Assessment) instrument and qualitative interviewing
Up to 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fred Hutchinson Cancer Center

Collaborators

National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Eric Chow, Fred Hutch/University of Washington Cancer Consortium

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 19, 2020

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

March 31, 2026

Study Registration Dates

First Submitted

August 29, 2019

First Submitted That Met QC Criteria

September 6, 2019

First Posted (Actual)

September 9, 2019

Study Record Updates

Last Update Posted (Actual)

April 8, 2026

Last Update Submitted That Met QC Criteria

April 7, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RG1005815
  • P30CA015704 (U.S. NIH Grant/Contract)
  • NCI-2019-05726 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • 10267 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
  • R21CA258105 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoma

Clinical Trials on Questionnaire Administration

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe